Quarterly report [Sections 13 or 15(d)]

Other current assets

v3.25.1
Other current assets
3 Months Ended
Mar. 31, 2025
Other current assets  
Other current assets

Note 8 — Other current assets

Other current assets consisted of the following (in thousands):

​

​

​

​

​

​

​

​

​

March 31, 

​

December 31, 

​

    

2025

​

2024

Research and development credits receivable

 

$

14,693

​

$

12,929

Prepayments

 

​

7,475

​

​

10,033

Clinical materials

 

​

—

​

​

59

VAT receivable

​

​

1,777

​

​

1,599

Other current assets

 

​

3,349

​

​

3,170

​

​

$

27,294

​

$

27,790

​

Research and development credits receivable as of March 31, 2025 primarily relate to the claim for the year ended December 31, 2024.